Determination of the biliary excretion of piperacillin in humans using a novel method

British Journal of Clinical Pharmacology

Volumn 62, Issue 3, 2006, Pages 304-308

  Ghibellini, Giulia ^a   Vasist, Lakshmi S ^a   Hill, Terence E ^a   Heizer, William D ^b   Kowalsky, Richard J ^a,b   Brouwer, Kim L R ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Biliary clearance; Biliary excretion; Gallbladder ejection fraction; Oroenteric catheter; Piperacillin

Indexed keywords

PIPERACILLIN;

ADULT; ARTICLE; ASPIRATION; BILIARY EXCRETION; BLOOD SAMPLING; CATHETER; DRUG CLEARANCE; DUODENUM; GALLBLADDER EJECTION FRACTION; GALLBLADDER FUNCTION; GAMMA SCINTIGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RELIABILITY; TECHNIQUE; URINALYSIS;

ADULT; BILE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; GASTROINTESTINAL AGENTS; HUMANS; IMINO ACIDS; MALE; ORGANOTECHNETIUM COMPOUNDS; PIPERACILLIN; RADIOPHARMACEUTICALS; SINCALIDE;

EID: 33747043121     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2006.02662.x     Document Type: Article

References (11)

1. Ryde M, Gustavsson S. Biliary excretion of olsalazine sodium in humans. Eur J Drug Metab Pharmacokinet 1987; 12: 17-24.
2. Ghibellini G, Johnson BM, Kowalsky RJ, Heizer WD, Brouwer KL. A novel method for the determination of biliary clearance in humans. AAPS J 2004; 6: e33.
3. Holmes B, Richards DM, Brogden RN, Heel RC. Piperacillin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 1984; 28: 375-425.
4. Krishnamurthy GT, Brown PH. Comparison of fatty meal and intravenous cholecystokinin infusion for gallbladder ejection fraction. J Nucl Med 2002; 43: 1603-10.
5. Ziessman HA, Muenz LR, Agarwal AK, ZaZa AA. Normal values for sincalide cholescintigraphy: comparison of two methods. Radiology 2001; 221: 404-10.
6. Tjandramaga TB, Mullie A, Verbesselt R, De Schepper PJ, Verbist L. Piperacillin: human pharmacokinetics after intravenous and intramuscular administration. Antimicrob Agents Chemother 1978; 14: 829-37.
7. Ford S, Kowalsky RJ, Heizer WD, Falen SW, Brouwer KLR. Evaluation of a novel method to quantify biliary excretion in humans. Clin Pharmacol Exp Ther 2002; 71 (P26): MPI-85.
8. Dong M, Sonoda Y, Kawamoto M, Konomi H, Kobayashi K, Yamaguchi K, Tanaka M. Duodenum is important for the sphincter of Oddi motor response to cholecystokinin octapeptide in conscious dogs. J Gastroenterol 2005; 40: 389-95.
9. Inoue H, Iannotti CA, Welling CM, Veile R, Donis-Keller H, Permutt MA. Human cholecystokinin type A receptor gene: cytogenetic localization, physical mapping, and identification of two missense variants in patients with obesity and non-insulin-dependent diabetes mellitus (NIDDM). Genomics 1997; 42: 331-5.
10. Westphal JF, Brogard JM, Caro-Sampara F, Adloff M, Blickle JF, Monteil H, Jehl F. Assessment of biliary excretion of piperacillin-tazobactam in humans. Antimicrob Agents Chemother 1997; 41: 1636-40.
11. Brogard JM, Jehl F, Blickle JF, Dorner M, Arnaud JP, Monteil H. Biliary pharmacokinetic profile of piperacillin: experimental data and evaluation in man. Int J Clin Pharmacol Ther Toxicol 1990; 28: 462-70.